BioSpace News Archive

Business

Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

Pillar Biosciences today announced that it has entered into an agreement with Labcorp to provide genomic testing for people with cancer.

October 14, 2021
·
2 min read
Business

CytRx Highlights ImmunityBio’s Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) (“ImmunityBio”) announced completion of enrollment in its Phase 2 trial studying a combination immunotherapy (Nant Cancer Vaccine)

October 14, 2021
·
7 min read
Business

Octant Bio Appoints Industry Veteran Mark Murcko as Strategic Advisor and Board Member

Today, Octant announced the appointment of Mark Murcko as Strategic Advisor and Board Member.

October 14, 2021
·
3 min read
Business

Kriya Therapeutics Appoints Theresa Heah, M.D., MBA as Chief Medical Officer and President of Kriya Ophthalmology™, a Newly Launched Division of Kriya Therapeutics

Kriya Therapeutics, Inc. , a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today announced the appointment of Theresa Heah, M.D., MBA as Chief Medical Officer.

October 14, 2021
·
4 min read
Drug Development

Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)

Gan & Lee Pharmaceuticals Co., Ltd. is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL-GLA) to a reference biologic.

October 14, 2021
·
2 min read
FEops HEARTguide Authorized by FDA for Unprecedented LAAo Planning Capabilities

FEops today announced that it received De Novo authorization from the U.S. Food and Drug Administration (FDA) for FEops HEARTguide™ pre-operative planning of left atrial appendage occlusion with the Boston Scientific WATCHMAN™ device*.

October 14, 2021
·
3 min read
Drug Development

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

First Wave BioPharma, Inc. today announced that it has dosed the first patient in a Phase 2b clinical trial investigating a topical formulation of niclosamide (FW-UP) as a potential treatment for patients with ulcerative proctitis (UP)

October 14, 2021
·
7 min read
Tentarix Biotherapeutics Emerges with $50 Million Series A

Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.

October 14, 2021
·
5 min read
FDA

Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis

Blade Therapeutics, Inc. today announced that the FDA has granted orphan drug designation for cudetaxestat for the potential treatment of systemic sclerosis (SSc). Cudetaxestat is an investigational non-competitive autotaxin inhibitor in clinical development for IPF.

October 14, 2021
·
4 min read
Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application

Altamira Therapeutics Ltd. today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration for its Bentrio nasal spray for protection against airborne allergens has cleared the Agency’s acceptance review.

October 14, 2021
·
3 min read